Lilly CEO rejects a decade-long AI disease-cure timeline
AI summary
Eli Lilly CEO Dave Ricks said it is unlikely AI will cure cancer and other major diseases within a decade, according to IT之家. He cited gaps in biological understanding and the bottleneck of randomized human trials, while expressing optimism that AI will produce steady, gradual progress in drug development. Gary Marcus amplified the disagreement by calling Anthropic CEO Dario Amodei’s timeline unrealistic.
In-depth insight
Ricks’s argument highlights the clinical-validation constraints behind AI-driven medical predictions, providing a counterpoint to Amodei’s optimistic roadmap.
This source provides an excerpt. Continue reading on the original site.